High-grade B-cell Lymphoma Clinical Trials

9 recruiting

High-grade B-cell Lymphoma Trials at a Glance

10 actively recruiting trials for high-grade b-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in New York, Portland, and Nashville. Lead sponsors running high-grade b-cell lymphoma studies include Memorial Sloan Kettering Cancer Center, British Columbia Cancer Agency, and Australasian Leukaemia and Lymphoma Group.

Browse high-grade b-cell lymphoma trials by phase

Treatments under study

About High-grade B-cell Lymphoma Clinical Trials

Looking for clinical trials for High-grade B-cell Lymphoma? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High-grade B-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High-grade B-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting

Study of CAR-T Therapy in Older Patients

High-grade B-cell LymphomaMultiple MyelomaLymphoma+3 more
Memorial Sloan Kettering Cancer Center154 enrolled1 locationNCT04300998
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Not Applicable

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+2 more
Hua-Jay J Cherng, MD40 enrolled1 locationNCT06693830
Recruiting

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Fondazione Italiana Linfomi - ETS200 enrolled20 locationsNCT06588205
Recruiting
Phase 2

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaStage III High Grade B-Cell Lymphoma+7 more
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT06736613
Recruiting
Phase 2

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+4 more
Australasian Leukaemia and Lymphoma Group39 enrolled1 locationNCT06287398